mutations provided The reality that, as explained below, CLL therapy is predicated to the presence or absence of such mutations. The existing consensus is usually that, aside from clonal mutations, subclonal mutations having a variant allelic frequency starting from five to 10% (and so down below the brink of detection by common molecular tactics)